Drug‐induced immune‐mediated thrombocytopenia secondary to durvalumab use
oleh: Sean C. Dougherty, Alia C. Lynch, Richard D. Hall
| Format: | Article |
|---|---|
| Diterbitkan: | Wiley 2021-06-01 |
Deskripsi
Abstract Immunotherapy is an expanding area of cancer treatment with significant promise. Despite their efficacy, checkpoint inhibitors are associated with a number of immune‐related adverse events; here, we described thrombocytopenia secondary todurvalumab.